Back to Search
Start Over
Estimating provisional margins of exposure for data-poor chemicals using high-throughput computational methods.
- Source :
-
Frontiers in pharmacology [Front Pharmacol] 2022 Oct 07; Vol. 13, pp. 980747. Date of Electronic Publication: 2022 Oct 07 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- Current computational technologies hold promise for prioritizing the testing of the thousands of chemicals in commerce. Here, a case study is presented demonstrating comparative risk-prioritization approaches based on the ratio of surrogate hazard and exposure data, called margins of exposure (MoEs). Exposures were estimated using a U.S. EPA's ExpoCast predictive model (SEEM3) results and estimates of bioactivity were predicted using: 1) Oral equivalent doses (OEDs) derived from U.S. EPA's ToxCast high-throughput screening program, together with in vitro to in vivo extrapolation and 2) thresholds of toxicological concern (TTCs) determined using a structure-based decision-tree using the Toxtree open source software. To ground-truth these computational approaches, we compared the MoEs based on predicted noncancer TTC and OED values to those derived using the traditional method of deriving points of departure from no-observed adverse effect levels (NOAELs) from in vivo oral exposures in rodents. TTC-based MoEs were lower than NOAEL-based MoEs for 520 out of 522 (99.6%) compounds in this smaller overlapping dataset, but were relatively well correlated with the same ( r <superscript> 2 </superscript> = 0.59). TTC-based MoEs were also lower than OED-based MoEs for 590 (83.2%) of the 709 evaluated chemicals, indicating that TTCs may serve as a conservative surrogate in the absence of chemical-specific experimental data. The TTC-based MoE prioritization process was then applied to over 45,000 curated environmental chemical structures as a proof-of-concept for high-throughput prioritization using TTC-based MoEs. This study demonstrates the utility of exploiting existing computational methods at the pre-assessment phase of a tiered risk-based approach to quickly, and conservatively, prioritize thousands of untested chemicals for further study.<br />Competing Interests: Author ML and HC are employed by Ramboll US Consulting, Inc. Authors MM, PM, and MA were employed by Scitovation, LLC. Author RC is employed by 21st Century Tox Consulting. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer NM declared a past coâauthorship with one of the authors GP to the handling Editor.<br /> (Copyright © 2022 Nicolas, Linakis, Minto, Mansouri, Clewell, Yoon, Wambaugh, Patlewicz, McMullen, Andersen and Clewell III.)
Details
- Language :
- English
- ISSN :
- 1663-9812
- Volume :
- 13
- Database :
- MEDLINE
- Journal :
- Frontiers in pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 36278238
- Full Text :
- https://doi.org/10.3389/fphar.2022.980747